WO1999061645A1 - Novel compound, wf00144 - Google Patents
Novel compound, wf00144 Download PDFInfo
- Publication number
- WO1999061645A1 WO1999061645A1 PCT/JP1999/002707 JP9902707W WO9961645A1 WO 1999061645 A1 WO1999061645 A1 WO 1999061645A1 JP 9902707 W JP9902707 W JP 9902707W WO 9961645 A1 WO9961645 A1 WO 9961645A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- reaction
- salt
- medicament
- brown
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 55
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 235000015097 nutrients Nutrition 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 241000282414 Homo sapiens Species 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 238000012258 culturing Methods 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241001207509 Phoma sp. Species 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000862 absorption spectrum Methods 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 claims description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 1
- 230000004110 gluconeogenesis Effects 0.000 abstract description 7
- 241001503951 Phoma Species 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
- 239000002609 medium Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 240000007817 Olea europaea Species 0.000 description 7
- -1 etc.) Chemical compound 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000001965 potato dextrose agar Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000004276 hyalin Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006783 corn meal agar Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002897 organic nitrogen compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G3/00—Glycosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Definitions
- the present invention relates to a new bioactive compound, hereinafter entitled WF00144 substance or its salt which is useful as a medicament.
- the present invention relates to a new bioactive compound, WF00144 substance or its salt.
- WF00144 substance or its salt which has an inhibitory activity against gluconeogenesis, to a process for preparation thereof, to a pharmaceutical composition comprising the same, which is useful as antidiabetic agents, and to a use thereof as a medicament.
- one object of this invention is to provide a novel compound
- WF00144 substance which is of use for treating and preventing diabetes, and the like.
- Another object of this invention is to provide a process for production of the WF00144 substance by fermentation of a WF00144 substance-producing microorganism in a nutrient medium.
- a further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, the WF00144 substance.
- Still further object of this invention is to provide a use of the WF00144 substance for treating and preventing diabetes and the like.
- the WF00144 substance can be produced by fermentation of the WF00144 substance-producing microorganism, especially, strain belonging to the genus Phoma such as Phoma sp. No. 00144 in a nutrient medium.
- the production of the WF00144 substance is not limited to the use of the particular organism described herein, which is given for the illustrative purpose only.
- This invention also includes the use of any mutants which are capable of producing the WF00144 substance including natural mutants as well as artificial mutants which can be produced from the described organism by conventional means such as irradiation of X- ray, ultra-violet radiation, genetic engineering treatment with N-methyl-N'- nitro-N-nitrosoguanidine, 2-aminopurine, and the like.
- the fungal strain No.00144 was originally isolated from a decayed leaf sample, collected at Ashiwada-mura, Minamitsuru-gun, Yamanashi-ken,
- the morphological characteristics were determined from the cultures on a Miura's LCA plate (Miura, K. and M. Kudo: Trans. Mycol. Soc. Japan, 11:116-118, 1970).
- Conidiomata were pycnidial, superficial or immersed, separate and brown to dark brown. Their shape was globose to subglobose, sometimes papillate, distinctly ostiolate, unilocular, and 60-90(-110) x 55-85 ⁇ m in size. Ostioles were 10-30(-35) ⁇ m in diameter.
- a few pycnidia formed l-3(-5) setae around the ostiole. The setae were dark brown, smooth, thick -walled, unbranched, somewhat flexuous, acute at the apex, and
- Pycnidial walls were thin and composed of 1-2 cells layer.
- the cells of pycnidial walls were thick-walled, brown, irregularly shaped, 3.5- 8 x 2.5-6.5 ⁇ m, and formed textura angularis.
- the inner pycnidial walls formed directly conidiogenous cells without conidiophores.
- the conidiogenous cells were discrete, acrogenous, hyaline, smooth, ampulliform to lageniform, and 3.5-8 x 2.5-6 ⁇ m.
- the tips of conidiogenous cells were 1.5- 2.5 ⁇ m wide.
- Conidia were enteroblastic, phialidic, hyaline, smooth, one- celled, globose to subglobose, with a small projection at the base, and 2.5-3.5 x (2-)2.5-3 ⁇ m.
- Vegetative hyphae were smooth, septate, brown and branched. The hyphal cells were cylindrical and 1.5-5 ⁇ m in width. Chlamydospores were not observed.
- Potato dextrose agar G Restrictedly, 2.0-3.0 cm (Difco 0013) S: Circular, plane to raised, felty to cottony, formed many pycnidia, greenish gray (27F2) to dark green (27F3) R:Dark gray (1F1) to reddish gray (12F2), sometimes producing reddish soluble pigments Czapek's solution agar* G:Restrictedly, 2.0-3.0 cm
- Emerson Yp Ss agar G Very restrictedly, 1.0-2.0 cm (Difco 0739)
- S Circular, plane, felty, radiately sulcate, formed pycnidia abundantly, dark gray (1F1)
- Corn meal agar G Restrictedly, 1.5-2.5 cm (Difco 0386)
- S Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4F2) to olive brown (4F3) at the center, and dark gray (1F1) to dark green (28F4) at the margin
- Oatmeal agar G Very restrictedly, 1.0-2.0 cm (Difco 0552)
- S Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4D2-4F2) to olive brown (4F3) at the center, and dark gray (1F1) at the margin
- G growth, measuring colony size in diameter, S: colony surface, R: reverse.
- the WF00144 substance is produced when the WF00144 substance- producing strain belonging to the genus Phoma is grown in a nutrient medium containing sources of assimilable carbon and nitrogen under aerobic conditions (e. g. shaking culture, submerged culture, etc.).
- the preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, sucrose, starch, fructose, glycerin, or the like.
- the preferred sources of nitrogen are peanut powder, yeast extract, peptone, gluten meal, cotton seed flour, soybean powder, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e. g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea or amino acid, or the like.
- ammonium salts e. g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.
- urea or amino acid or the like.
- the carbon and nitrogen sources though advantageously employed in combination, need not to be used in their pure form because less pure materials, which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.
- medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, zinc salts, iron salts, or cobalt salts, or the like.
- a defoaming agent such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone, or the like may be added. Agitation and aeration of the culture mixture may be accomplished in a variety of ways, such as agitation by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermenter, and the like.
- the fermentation is usually conducted at a temperature between about
- the culture broth is then subjected for recovery of the WF00144 substance to various procedures conventionally used for recovery and purification of biological active substance, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from an appropriate solvent or a mixture thereof.
- the WF00144 substance obtained can be converted to its salt in a conventional manner.
- the salt of the WF00144 substance may include a salt with an organic or inorganic base such as alkaline metal salt (e.g. sodium or potassium salt ), alkaline earth metal salt (e.g. calcium or magnesium salt ), organic amine salt (e.g. ethanolamine salt, etc.) amino acid salt (e.g. arginine salt, lysine salt, histidine salt, etc.) and the like.
- alkaline metal salt e.g. sodium or potassium salt
- alkaline earth metal salt e.g. calcium or magnesium salt
- organic amine salt e.g. ethanolamine salt, etc.
- amino acid salt e.g. arginine salt, lysine salt, histidine salt, etc.
- the WF00144 substance as obtained has the following physico-chemical properties:
- the WF00144 substance possesses pharmacological activities such as the inhibitory activity against gluconeogenesis, and the like, and therefore are useful for the treatment and prevention of diabetes, and the like.
- the WF00144 substance may be useful for various diseases because of its useful pharmaceutical activity such as an inhibitory activity against gluconeogenesis, and so on.
- Hepatocytes were prepared from 24 hours starved male Wistar rat (150- 200 g) by the collagenase perfusion technique. Cells were cultured in William's E medium containing 5%(v/v) fetal bovine serum, O.lmg/ml kanamycin for 6 hours at 96-well tissue culture plates. Cells were washed with phosphate-buffered saline and incubated with Dulbecco's Modified Eagle's
- Gluconeogenesis rate was performed as glucose value derived from pyruvate.
- the half -maximal inhibitory concentration of WF00144 substance on rat hepatocytes gluconeogenesis was 0.08 ⁇ g/ml.
- the pharmaceutical composition of this invention can be used in the form of pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the WF00144 substance or its pharmaceutically acceptable salt, as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral administrations.
- the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, liniments, eye drops, lotion, gel, cream, and any other form suitable for use.
- the carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used.
- the above pharmaceutical composition For applying the above pharmaceutical composition to a patient including human beings and animals suffered from diabetes, it is preferable to apply it by intravenous, intramuscular, topical or oral administration. While the dosage of therapeutically effective amount of the WF00144 substance varies from and also depends upon the age and condition of each individual patient to be treated, the optimal dosage for the treatment of the patient suffered from diabetes may be selected from the range of 0.01 - 50 mg of the WF00144 substance per kg weight of the patient.
- the cultured broth (20 L; containing 1.8g of WF00144 substance) was filtered with an aid of diatomaceous earth.
- the filtered mycelium was extracted with 20L of acetone by intermittent mixing for 1 hr.
- the acetone extract was filtered and diluted with twice volume of deionized water.
- the diluted filtrate was passed through a column (2L) of Diaion HP-20 (Mitsubishi Chemical Co., Ltd.). The column was washed with 50% aqueous methanol and eluted with 80% methanol.
- the eluate (4L) was concentrated in vacuo to one liter and added with 3 liters of 0.07% aqueous trifluoroacetic acid, and then applied on a column (2L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid.
- the column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid.
- the fractions containing the WF00144 substance were combined and applied on a column (1L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid.
- the column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid.
- the fractions containing the WF00144 substance were combined and concentrated in vacuo to give residual water.
- the residual water was twice extracted with equal volume of ethyl acetate.
- the extract was concentrated in vacuo to small volume and added with several volumes of n-hexane, and then concentrated in vacuo to give 810mg of crude WF00144 substance as a powder.
- the 60mg of crude WF00144 powder was dissolved in acetonitrile (0.6ml) and subjected to preparative HPLC, YMC-packed column (ODS-AM SH-343-5AM S-5 (20 mm ⁇ x 250mmL; YMC Co., Ltd.) with 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid as a mobile phase and flow rate of 9.9 ml/min. Elution was monitored by analytical HPLC indicated below. The portion corresponding to the purified WF00144 substance was concentrated in vacuo to give residual water. This residue was twice extracted with equal volume of ethyl acetate and concentrated in vacuo to small volume.
- the concentrated extract was added with several volumes of n-hexane and dried in vacuo to give 36mg of purified WF00144 substance as a white powder.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
The present invention provides a new bioactive compound, WF00144 substance or its salt which has an inhibitory activity against gluconeogenesis, and a process for production of the same, which comprises culturing a WF00144 substance-producing strain belonging to the genus Phoma in a nutrient medium and recovering the WF00144 substance. Also provided are a pharmaceutical composition containing the WF00144 substance or pharmaceutically acceptable salt thereof, a use of the WF00144 substance as a medicament and use of the WF00144 substance for the manufacture of a medicament for therapeutic treatment or prevention of diabetes in human or animal.
Description
DESCRIPTION
NOVEL COMPOUND, WF00144
TECHNICAL FIELD
The present invention relates to a new bioactive compound, hereinafter entitled WF00144 substance or its salt which is useful as a medicament.
DISCLOSURE OF INVENTION
The present invention relates to a new bioactive compound, WF00144 substance or its salt.
More particularly, it relates to a novel compound, WF00144 substance or its salt which has an inhibitory activity against gluconeogenesis, to a process for preparation thereof, to a pharmaceutical composition comprising the same, which is useful as antidiabetic agents, and to a use thereof as a medicament.
Accordingly, one object of this invention is to provide a novel compound,
WF00144 substance which is of use for treating and preventing diabetes, and the like.
Another object of this invention is to provide a process for production of the WF00144 substance by fermentation of a WF00144 substance-producing microorganism in a nutrient medium.
A further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, the WF00144 substance.
Still further object of this invention is to provide a use of the WF00144 substance for treating and preventing diabetes and the like.
The WF00144 substance can be produced by fermentation of the WF00144 substance-producing microorganism, especially, strain belonging to
the genus Phoma such as Phoma sp. No. 00144 in a nutrient medium.
It is to be understood that the production of the WF00144 substance is not limited to the use of the particular organism described herein, which is given for the illustrative purpose only. This invention also includes the use of any mutants which are capable of producing the WF00144 substance including natural mutants as well as artificial mutants which can be produced from the described organism by conventional means such as irradiation of X- ray, ultra-violet radiation, genetic engineering treatment with N-methyl-N'- nitro-N-nitrosoguanidine, 2-aminopurine, and the like.
Characteristics of producing strain No .00144
The fungal strain No.00144 was originally isolated from a decayed leaf sample, collected at Ashiwada-mura, Minamitsuru-gun, Yamanashi-ken,
Japan. This organism grew restrictedly on various culture media, and formed olive brown to dark green colonies. On or in the agar media, the strain produced pycnidial conidiomata. The conidiomata were globose to subglobose, brown, and formed ampulliform conidiogenous cells on their inner walls. Conidia were hyaline, one-celled and globose to subglobose. The strain did not formed teleomorph. Its mycological characteristics were as follows.
Cultural characteristics on various agar media are summarized in Table 1. Culture on potato dextrose agar grew restrictedly, attaining 2.0-3.0 cm in diameter two weeks later at 25°C. This colony surface was plane to raised, felty to cottony, and greenish gray to dark green. Many conidiomata were formed on or in the media. The reverse color was dark gray to reddish gray, and sometimes producing reddish soluble pigments. Colonies on corn meal agar spread more restrictedly than on potato dextrose agar, attaining 1.5-2.5 cm in diameter under the same conditions. The surface was plane, felty, exudate, brownish gray to olive brown at the center, and dark gray to dark green at the margin. The reverse was dark gray to dark green. Conidiomata were abundantly formed.
The morphological characteristics were determined from the cultures on a Miura's LCA plate (Miura, K. and M. Kudo: Trans. Mycol. Soc. Japan, 11:116-118, 1970). Conidiomata were pycnidial, superficial or immersed,
separate and brown to dark brown. Their shape was globose to subglobose, sometimes papillate, distinctly ostiolate, unilocular, and 60-90(-110) x 55-85 μm in size. Ostioles were 10-30(-35) μm in diameter. In old culture, a few pycnidia formed l-3(-5) setae around the ostiole. The setae were dark brown, smooth, thick -walled, unbranched, somewhat flexuous, acute at the apex, and
15-24 x 4-6μm. Pycnidial walls were thin and composed of 1-2 cells layer. The cells of pycnidial walls were thick-walled, brown, irregularly shaped, 3.5- 8 x 2.5-6.5 μm, and formed textura angularis. The inner pycnidial walls formed directly conidiogenous cells without conidiophores. The conidiogenous cells were discrete, acrogenous, hyaline, smooth, ampulliform to lageniform, and 3.5-8 x 2.5-6 μm. The tips of conidiogenous cells were 1.5- 2.5 μm wide. Conidia were enteroblastic, phialidic, hyaline, smooth, one- celled, globose to subglobose, with a small projection at the base, and 2.5-3.5 x (2-)2.5-3 μm. Vegetative hyphae were smooth, septate, brown and branched. The hyphal cells were cylindrical and 1.5-5 μm in width. Chlamydospores were not observed.
Strain No .00144 was able to grow at the temperature range from 5 to 30°C, with the growth optimum at 21 to 24°C. These temperature data were determined on potato dextrose agar (made by NISSUI). On the basis of comparing the morphological characteristics with fungal taxonomic criteria by von Arx (J. A. von Arx: The Genera of Fungi - Sporulating in Pure Culture. 3rd ed., pp.315, J. Cramer, Vaduz, 1974) and by Sutton (B . C. Sutton: The Coelomycetes - Fungi Imperfecti with Pycnidia, Acervuli and Stroma., pp.696, Commonwealth Mycological Institute, Kew, 1980.), strain No .00144 was considered to belong to the coelomycete genus
Phoma Sacc. 1880 (Sphaeropsidales). Thus, we identified this isolate as one strain of the genus Phoma , and named it Phoma sp. No .00144. The strain has been deposited to the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan, as FERM BP-6360 (deposited date : May 19,
1998) under the Budapest Treaty.
Table 1. Cultural characteristics of strain No .00144.
Media Cultural characteristics
Malt extract agar* G:Rather restrictedly, 2.5-3.5 cm
S: Circular, plane, felty, radiately sulcate, sometimes exudate, formed some pycnidia, dark green (28F3-28F4) to dull green (28D3-28E3) R: Grayish brown (8F3) to dark brown
(8F4-8F5), sometimes producing reddish soluble pigments
Potato dextrose agar G:Restrictedly, 2.0-3.0 cm (Difco 0013) S: Circular, plane to raised, felty to cottony, formed many pycnidia, greenish gray (27F2) to dark green (27F3) R:Dark gray (1F1) to reddish gray (12F2), sometimes producing reddish soluble pigments Czapek's solution agar* G:Restrictedly, 2.0-3.0 cm
S: Circular, plane or somewhat raised, felty, radiately sulcate or wrinkly, exudate, formed pycnidia abundantly, olive (1F3-1E4) to olive gray (1F2), and reddish brown (8E3-8E5) at the margin
R:Dark brown (8F3-8F4), and light brown (7D4) to brown (7E4) at the margin, sometimes producing orange soluble pigments Sabouraud dextrose agar G:Restrictedly, 2.0-3.0 cm
(Difco 0190) S: Circular, plane to centrally raised, felty, radiately sulcate, formed no pycnidia, dull green (28 E4) to dark green (28 F3), and greenish gray (28D2) at the margin R:Dark ruby (12F3) to dark purple (14F3),
sometimes producing reddish soluble pigments
Emerson Yp Ss agar G:Very restrictedly, 1.0-2.0 cm (Difco 0739) S: Circular, plane, felty, radiately sulcate, formed pycnidia abundantly, dark gray (1F1)
R:Dark gray (1F1) to dark blue (22F4)
Corn meal agar G:Restrictedly, 1.5-2.5 cm (Difco 0386) S: Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4F2) to olive brown (4F3) at the center, and dark gray (1F1) to dark green (28F4) at the margin
R:Dark gray (1F1) to dark green (28F4)
MY20 agar* G .-Restrictedly, 1.5-2.5 cm
S: Circular, plane, felty, sometimes funiculose, radiately sulcate or wrinkly, formed no pycnidia, dull green (28D3-28E3) or brownish gray (4E2) to olive brown (4E3)
R: Grayish brown (7F3) to dark brown (7F4), and light brown (7D4) to brown (7E4) at the margin, sometimes producing pale orange soluble pigments
Oatmeal agar G:Very restrictedly, 1.0-2.0 cm (Difco 0552) S: Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4D2-4F2) to olive brown (4F3) at the center, and dark gray (1F1) at the margin
Abbreviation G: growth, measuring colony size in diameter, S: colony surface, R: reverse.
* : The compositions of malt extract agar, Czapek's solution agar and MY20 agar were based on JCM Catalogue of Strains (Nakase, T., 6th ed., pp.617, Japan Collection of Microorganisms, the Institute of Physical and Chemical Research, Saitama, 1995).
These characteristics were observed after 14 days of incubation at 25°C. The color descriptions were based on Methuen Handbook of Colour (Kornerup, A. and J. H. Wanscher, 3rd ed., pp.252, Methuen, London, 1978).
Production of the WF00144 substance
The WF00144 substance is produced when the WF00144 substance- producing strain belonging to the genus Phoma is grown in a nutrient medium containing sources of assimilable carbon and nitrogen under aerobic conditions (e. g. shaking culture, submerged culture, etc.).
The preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, sucrose, starch, fructose, glycerin, or the like.
The preferred sources of nitrogen are peanut powder, yeast extract, peptone, gluten meal, cotton seed flour, soybean powder, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e. g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea or amino acid, or the like.
The carbon and nitrogen sources, though advantageously employed in combination, need not to be used in their pure form because less pure materials, which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.
When desired, there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, zinc salts, iron salts, or cobalt salts, or the like.
If necessary, especially when the culture medium foams seriously a defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone, or the like may be added. Agitation and aeration of the culture mixture may be accomplished in a variety of ways, such as agitation by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermenter, and the like.
The fermentation is usually conducted at a temperature between about
10 °C and 40 °C, preferably 20 °C to 35 °C, for a period of about 24 hours to 120 hours, which may be varied according to fermentation conditions and
scales.
When the fermentation is completed, the culture broth is then subjected for recovery of the WF00144 substance to various procedures conventionally used for recovery and purification of biological active substance, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from an appropriate solvent or a mixture thereof.
The WF00144 substance obtained can be converted to its salt in a conventional manner. The salt of the WF00144 substance may include a salt with an organic or inorganic base such as alkaline metal salt (e.g. sodium or potassium salt ), alkaline earth metal salt (e.g. calcium or magnesium salt ), organic amine salt (e.g. ethanolamine salt, etc.) amino acid salt (e.g. arginine salt, lysine salt, histidine salt, etc.) and the like.
The WF00144 substance as obtained has the following physico-chemical properties:
(1) Appearance: white powder (2) Molecular formula : 2 H40U9
(3) Elementary Analysis:
Calcd for C27H40O9 ■ 1/2H20 C 62.65, H 7.98 Found:
C 62.22, H 7.97
(4) Molecular weight:
ESI-MS(negative): m/z 507 (M-H)~ (Calcd .Molecular weight: 508.61) (5) Melting point:
85T89 °C (dec)
(6) Optical rotation:
[α]D(23°C) =-16 ° (c=0.2, in chloroform)
(7) Ultraviolet absorption spectrum: λmax (methanol): 275 nm (ε =8000)
(8) Solubility: Soluble: acetonitrile, chloroform, ethyl acetate, dimethylsulfoxide Slightly soluble: n-hexane Insoluble: water
(9) Color reaction: Positive: cerium sulfate reaction, iodine vapor reaction, Negative: Molish's reaction, ninhydrin reaction, Dragendorff reaction,
Ehrlich's reaction
(10) Thin layer chromatography (TLC):
Stationary phase Developing solvent Rf value
Silica Gel 60 n-hexane : ethyl acetate : acetic acid 0.25 F254* ( 50: 50: l, v/v )
* made by E. Merck
(11) High Performance Liquid Chromatography (HPLC): Condition:
Column: YMC-Pack Pro C18 AS-302 * *(4.6 mmφ x 150mmL) Mobile phase: 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid
Flow rate: 1 ml/min
Detection: UV at 280 nm
Retention time: 7.9 min * *: made by YMC Co., Ltd.
(12) Infrared absorption spectrum: vmax (KBr): 3480, 2980, 2930, 1730, 1710, 1650, 1620, 1460, 1380, 1160, 1140 cm 1
(13) JH Nuclear magnetic resonance spectrum: (500 MHz, CD3CN) δ(ppm):
15.0 (IH, br s), 7.76 (IH, d, 5), 5.97 (IH, d, 5), 5.74 (IH, br s), 4.22 (IH, dd, 10.5, 9.5), 4.13 (IH, dd, 10.5, 4.5), 3.20 - 3.13 (2H, m), 2.63 (IH, m), 2.53 (IH, dd, 13, 10), 2.18 (IH, m), 2.12 (3H, br s), 2.02 (IH, m), 1.85 (IH, s), 1.80 (IH, m), 1.53 (3H, s), 1.57 - 1.47 (2H, m), 1.37 (IH, m), 1.27 (IH, m), 1.27 (3H, s), 1.16 (3H, s), 1.12 (IH, dd,
12, 14), 0.82 (3H, t, 7), 0.68 (3H, d, 6.5).
(14) 13C Nuclear magnetic resonance spectrum: (125 MHz, CDCN) δ(ppm):
217.4 (s), 209.3 (s), 173.5 (d), 170.9 (s), 167.5 (s), 153.5 (s), 119.7 (d), 102.7 (d), 78.1 (s), 69.6 (t), 68.9 (s), 50.5 (d), 50.2 (s), 48.4 (t), 46.4 (t), 45.7 (d), 41.9 (t), 41.5 (d), 41.3 (d), 31.0 (q), 30.1 (d), 24.6 (q), 22.5 (t),21.3 (q), 20.6 (q), 19.1 (q), 13.4 (q).
(15) Nature of substance: acidic substance.
Biological properties of the WF00144 substance
The WF00144 substance possesses pharmacological activities such as the inhibitory activity against gluconeogenesis, and the like, and therefore are useful for the treatment and prevention of diabetes, and the like.
And further, the WF00144 substance may be useful for various diseases because of its useful pharmaceutical activity such as an inhibitory activity against gluconeogenesis, and so on.
As examples for showing biological activities of the WF00144 substance, some biological data are explained in the following.
Test (Effect of WF00144 substance on rat hepatocytes gluconeogenesis)
Hepatocytes were prepared from 24 hours starved male Wistar rat (150- 200 g) by the collagenase perfusion technique. Cells were cultured in William's E medium containing 5%(v/v) fetal bovine serum, O.lmg/ml kanamycin for 6 hours at 96-well tissue culture plates. Cells were washed with phosphate-buffered saline and incubated with Dulbecco's Modified Eagle's
Medium without glucose, supplemented with 20mM pyruvate, lxlO"7 M glucagon, O.lmg/ml kanamycin and l%(v/v) fetal bovine serum. After 15 hours, glucose produced into the medium was determined by enzymatically method. Gluconeogenesis rate was performed as glucose value derived from pyruvate.
The half -maximal inhibitory concentration of WF00144 substance on rat hepatocytes gluconeogenesis was 0.08μg/ml.
The pharmaceutical composition of this invention can be used in the form of pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the WF00144 substance or its pharmaceutically acceptable salt, as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral administrations. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, liniments, eye drops, lotion, gel, cream, and any other form suitable for use.
The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used.
For applying the above pharmaceutical composition to a patient including human beings and animals suffered from diabetes, it is preferable to apply it by intravenous, intramuscular, topical or oral administration. While the dosage of therapeutically effective amount of the WF00144 substance varies from and also depends upon the age and condition of each individual patient to be treated, the optimal dosage for the treatment of the patient suffered from diabetes may be selected from the range of 0.01 - 50 mg of the WF00144 substance per kg weight of the patient.
The following examples are given for the purpose of illustrating the present invention.
Example 1:
(1) Fermentation of Phoma sp. No.00144 for the production of the WF00144 substance
An aqueous seed medium (30ml) containing sucrose 4%, glucose 1%, soluble starch 2%, cotton seed meal 3%, soybean flour 1.5%, KH2P04 1%, CaC03 0.2% was placed in a 100-ml Erlenmeyer flask and was sterilized at 121°C for 30 minutes. A loopful of a slant culture of Phoma sp. No.00144 was inoculated in a seed flask. The inoculated flask was shaken on a rotary shaker
(220 rpm, 5.1 cm throw) at 25°C for 4 days, and 3.2ml of the seed culture was transferred to 160-ml of the same sterile seed medium in the 500 ml Erlenmeyer flasks. The flasks were shaken on a rotary shaker (220rρm, 5.1 cm throw) at 25 °C for 4 days, and 480 ml (three flasks) of second seed culture was inoculated to 20 liters of sterile production medium containing of glucose
1 %, starch acid hydrolysates 3%, wheat germ 1%, KH2P04 1%, Adecanol LG- 109 (deforming agent, Asahi Denka Co., Ltd.) 0.05%, Silicone KM-70 (deforming agent, Shin-Etsu Chemical Co., Ltd.) 0.05% in a 30-liter jar fermentor. Fermentation was carried out at 25 °C for 7 days under aeration of 20 liters / minute and agitation of 400rpm.
The production of the WF00144 substance in the fermentation broth was monitored by HPLC analysis indicated below.
Analytical condition: Column; YMC-Pack Pro C18 AS-302 (4.6 mmφ x 150mmL, made by YMC
Co., Ltd.)
Mobile phase; 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid
Flow rate; lml/min
Detection; UV at 280nm Retention time: 7.9min.
(2) Isolation of WF00144 substance
The cultured broth (20 L; containing 1.8g of WF00144 substance) was filtered with an aid of diatomaceous earth. The filtered mycelium was extracted with 20L of acetone by intermittent mixing for 1 hr. The acetone extract was filtered and diluted with twice volume of deionized water. The diluted filtrate was passed through a column (2L) of Diaion HP-20 (Mitsubishi Chemical Co., Ltd.). The column was washed with 50% aqueous methanol and eluted with 80% methanol. The eluate (4L) was concentrated in
vacuo to one liter and added with 3 liters of 0.07% aqueous trifluoroacetic acid, and then applied on a column (2L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid. The column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid. The fractions containing the WF00144 substance were combined and applied on a column (1L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid. The column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid. The fractions containing the WF00144 substance were combined and concentrated in vacuo to give residual water. The residual water was twice extracted with equal volume of ethyl acetate. The extract was concentrated in vacuo to small volume and added with several volumes of n-hexane, and then concentrated in vacuo to give 810mg of crude WF00144 substance as a powder.
The 60mg of crude WF00144 powder was dissolved in acetonitrile (0.6ml) and subjected to preparative HPLC, YMC-packed column (ODS-AM SH-343-5AM S-5 (20 mmφ x 250mmL; YMC Co., Ltd.) with 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid as a mobile phase and flow rate of 9.9 ml/min. Elution was monitored by analytical HPLC indicated below. The portion corresponding to the purified WF00144 substance was concentrated in vacuo to give residual water. This residue was twice extracted with equal volume of ethyl acetate and concentrated in vacuo to small volume.
The concentrated extract was added with several volumes of n-hexane and dried in vacuo to give 36mg of purified WF00144 substance as a white powder.
Analytical condition:
Column; YMC-Pack Pro C18 AS-302 (4.6 mmφ x 150mmL)
Mobile phase; 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid
Flow rate; 1 ml/min
Detection; UV at 280nm Retention time ; 7.9min.
Claims
1. WF00144 substance of the following physico-chemical properties or its salt:
(1) Molecular formula : 27H40U9
(2) Elementary Analysis:
Calcd for C27H40O9- l/2H2O C 62.65, H 7.98
Found:
C 62.22, H 7.97
(3) Molecular weight:
ESI-MS(negative): m/z 507 (M-H)~ (Calcd .Molecular weight : 508.61)
(4) Melting point:
85-89 ┬░C (dec)
(5) Optical rotation:
[╬▒]D(23┬░Q =-16 ┬░ (c=0.2, in chloroform) (6) Ultraviolet absorption spectrum: ╬╗max (methanol): 275 nm (╬╡=8000)
(7) Solubility:
Soluble: acetonitrile, chloroform, ethyl acetate, dimethylsulfoxide Slightly soluble: n-hexane Insoluble: water
(8) Color reaction:
Positive: cerium sulfate reaction, iodine vapor reaction, Negative: Molish's reaction, ninhydrin reaction, Dragendorff reaction, Ehrlich's reaction (9) Infrared absorption spectrum: vmax (KBr): 3480, 2980, 2930, 1730, 1710, 1650, 1620, 1460, 1380, 1160, 1140 cm 1 (10) 2H Nuclear magnetic resonance spectrum: (500 MHz, CD3CN) ╬┤(ppm): 15.0 (IH, br s), 7.76 (IH, d, 5), 5.97 (IH, d, 5), 5.74 (IH, br s),
4.22 (IH, dd, 10.5, 9.5), 4.13 (IH, dd, 10.5, 4.5), 3.20 - 3.13 (2H, m), 2.63 (IH, m), 2.53 (IH, dd, 13, 10), 2.18 (IH, m), 2.12 (3H, br s), 2.02 (IH, m), 1.85 (IH, s), 1.80 (IH, m), 1.53 (3H, s), 1.57 - 1.47 (2H, m), 1.37 (IH, m), 1.27 (IH, m), 1.27 (3H, s), 1.16 (3H, s), 1.12 (IH, dd, 12, 14), 0.82 (3H, t, 7), 0.68 (3H, d, 6.5).
(11) 13C Nuclear magnetic resonance spectrum: (125 MHz, CDCN) ╬┤(ppm):
217.4 (s), 209.3 (s), 173.5 (d), 170.9 (s), 167.5 (s), 153.5 (s), 119.7 (d), 102.7 (d), 78.1 (s), 69.6 (t), 68.9 (s), 50.5 (d), 50.2 (s), 48.4 (t), 46.4 (t), 45.7 (d), 41.9 (t), 41.5 (d), 41.3 (d), 31.0 (q),
30.1 (d), 24.6 (q), 22.5 (t),21.3 (q), 20.6 (q), 19.1 (q), 13.4 (q).
2. A process for production of the WF00144 substance or its salt, which comprises culturing a WF00144 substance -producing microorganism in a nutrient medium and recovering the WF00144 substance or its salt from the resultant cultured broth.
3. Biological pure culture of Phoma sp. No. 00144 (FERM BP-6360).
4. A pharmaceutical composition containing the WF00144 substance or pharmaceutically acceptable salt thereof.
5. A use of the WF00144 substance as a medicament.
6. A method for treating or preventing diabetes which comprises administrating the WF00144 substance to human or animal.
7. Use of the WF00144 substance for the manufacture of a medicament for therapeutic treatment or prevention of diabetes in human or animal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54687699A JP2002510335A (en) | 1998-05-28 | 1999-05-21 | New compound WF00144 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP3771A AUPP377198A0 (en) | 1998-05-28 | 1998-05-28 | Novel compound WF00144 |
| AUPP3771 | 1998-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999061645A1 true WO1999061645A1 (en) | 1999-12-02 |
Family
ID=3808018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1999/002707 WO1999061645A1 (en) | 1998-05-28 | 1999-05-21 | Novel compound, wf00144 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2002510335A (en) |
| AU (1) | AUPP377198A0 (en) |
| WO (1) | WO1999061645A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003091436A1 (en) * | 2002-04-26 | 2003-11-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel 35 kd protein |
| CN110878325A (en) * | 2019-12-16 | 2020-03-13 | 赵兰坤 | Optimized glutamic acid fermentation medium |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07149631A (en) * | 1993-11-30 | 1995-06-13 | Nkk Corp | Inhibitor of aldose reductase |
| GB2323845A (en) * | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
-
1998
- 1998-05-28 AU AUPP3771A patent/AUPP377198A0/en not_active Abandoned
-
1999
- 1999-05-21 WO PCT/JP1999/002707 patent/WO1999061645A1/en active Application Filing
- 1999-05-21 JP JP54687699A patent/JP2002510335A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07149631A (en) * | 1993-11-30 | 1995-06-13 | Nkk Corp | Inhibitor of aldose reductase |
| GB2323845A (en) * | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 123, no. 15, 9 October 1995, Columbus, Ohio, US; abstract no. 188618, YAMADA, MASASHI ET AL: "Aldose reductase inhibitors containing 2-hydroxy-p-benzoquinones" XP002110276 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003091436A1 (en) * | 2002-04-26 | 2003-11-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel 35 kd protein |
| EP1498487A1 (en) * | 2002-04-26 | 2005-01-19 | Fujisawa Pharmaceutical Co., Ltd. | Novel 35 kd protein |
| EP1498487A4 (en) * | 2002-04-26 | 2006-11-29 | Astellas Pharma Inc | Novel 35 kd protein |
| US7371842B2 (en) | 2002-04-26 | 2008-05-13 | Astellas Pharma Inc. | Polynucleotide encoding a 35 KDA protein thats binds to WF00144 |
| CN110878325A (en) * | 2019-12-16 | 2020-03-13 | 赵兰坤 | Optimized glutamic acid fermentation medium |
| CN110878325B (en) * | 2019-12-16 | 2021-05-25 | 呼伦贝尔东北阜丰生物科技有限公司 | Optimized glutamic acid fermentation medium |
Also Published As
| Publication number | Publication date |
|---|---|
| AUPP377198A0 (en) | 1998-06-18 |
| JP2002510335A (en) | 2002-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0431350B1 (en) | New polypeptide compound and a process for preparation thereof | |
| EP0352646B1 (en) | Fr901228 substance and preparation thereof | |
| US5037809A (en) | Antimicrobial agent, FR109615 and production thereof | |
| US5854276A (en) | Substance WF16616, process for production thereof, and use thereof | |
| KR970009151B1 (en) | WS-9326A, WS-9326B Compounds and Derivatives thereof | |
| WO1999061645A1 (en) | Novel compound, wf00144 | |
| US6730776B1 (en) | WF14573 or its salt, production thereof and use thereof | |
| EP1087987B1 (en) | A compound, wf002, production thereof and use thereof | |
| US4803074A (en) | FR-900848 substance and preparation thereof | |
| EP0318254B1 (en) | Tripeptide derivatives | |
| EP0380373B1 (en) | Polycyclic compounds and their production | |
| US4910017A (en) | New compounds WF 2015 A and B | |
| EP0504711B1 (en) | Compound UCA1064-B | |
| WO2001029182A1 (en) | Novel compound, wf217 | |
| WO1999063102A1 (en) | ANTIDIABETIC ACTIVE COMPOUND(S) WF19353 AND PROCESS FOR THEIR FERMENTATIVE PREPARATION USING A FUNGUS OF THE GENUS $i(HELICOMYCES) | |
| EP0333177A2 (en) | FR-900493 substance, a process for its production and a pharmaceutical composition containing the same | |
| WO1995018142A1 (en) | Wf15604 substances | |
| JP3176672B2 (en) | Novel glutarimide antibiotic having antiviral activity and method for producing the same | |
| EP1489187A1 (en) | Osteoclast differentiation inhibitors | |
| JP2000053674A (en) | Ec1007 compound | |
| JPH08176157A (en) | Novel bioactive substance epostatin, method for producing the same and use thereof | |
| JPH0764851B2 (en) | Reveromycin B, C, and D, production method thereof, and antitumor agent and antifungal agent | |
| GB2293379A (en) | WF17819 substance | |
| JPH0931088A (en) | Wb968 substance group and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA CN JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| 122 | Ep: pct application non-entry in european phase |